Project Grant R01HL179063
Award Date 6/10/26
Completion Date 2/28/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- Federal Grant Award Summary The University of Virginia received a $644,997 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 21, 2025, with completion expected by May 31, 2030. This research project aims to identify and validate plasma proteomic biomarkers that predict disease progression and survival outcomes in idiopathic pulmonary fibrosis (IPF), a chronic progressive lung disease with poor...
- Federal Project Grant Summary The University of Virginia received a $1,597,663 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion targeted for May 31, 2030. The grant funds research to investigate the role of oxidation-specific epitope immunoglobulin A (IgA-OSE) in idiopathic pulmonary fibrosis (IPF) pathogenesis. The research will characterize the antibody response...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $248,999 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2028. This award supports research investigating the mechanotransduction regulation of cellular metabolism in idiopathic pulmonary fibrosis (IPF), a progressive scarring disease with limited therapeutic options. The research...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Virginia a $1,423,306 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for a project titled "Modeling Intra- and Inter-Cellular Networks for TRPC6-Dependent Cardiac Fibrosis." The award was obligated on August 15, 2025, with a completion date of April 30, 2029. The research addresses cardiac fibrosis—a major complication of myocardial infarction...
- Virginia Commonwealth University was awarded a $210,611.86 Project Grant from the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute on January 31, 2021. The grant supports research under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate "Tissue Stiffness Promotes Pro-Fibrotic Metabolic Dysregulation in Lung Fibrosis." This two-year project aims to foster basic research on the relationship between tissue...
- Federal Grant Award Summary The University of Virginia received a $2.16 million Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2029. This award supports fundamental biomedical research investigating the mechanisms regulating inflammatory fibroblasts in wound healing. The project addresses a critical gap in understanding immune-stromal crosstalk...
- Federal Grant Award Summary The University of Virginia received an $802,611 Project Grant award dated September 15, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of advanced cardiac magnetic resonance imaging (CMR) methods to quantify epicardial adipose tissue (EAT) composition and characterize fatty acid composition in human subjects. The project will deliver improved...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Virginia a $2,310,685 Project Grant on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and apply the MetaboxCan analytical method for investigating chronic obstructive pulmonary disease (COPD) pathogenesis. The project, which extends through May 31, 2029, integrates genome-wide association studies (GWAS) with metabolomics and genomics data to...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $1,376,933 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for April 30, 2029. The award funds research into fibroblast-mediated resolution of basal metaplasia in lung fibrosis, specifically investigating how specialized alveolar fibroblasts expressing the...
- Federal Grant Award Summary The University of Virginia received a $1.46 million Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded on April 14, 2026, with completion scheduled for April 13, 2029. The grant funds research investigating the therapeutic potential of recombinant human MG53 (RHMG53) protein to treat lung injuries induced by vesicant agents such as sulfur mustard and nitrogen mustard....